MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Motawi, Tarek M K ^a   Rizk, Sherine M ^a   Shaker, Olfat G ^b   Mokhtar, Olfat Z H ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Cairo University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MICRORNA 122; MICRORNA 21; MICRORNA 221; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MICRORNA;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DRUG RESPONSE; EGYPTIAN; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; EGYPT; GENE EXPRESSION PROFILING; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER FUNCTION TEST; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; EGYPT; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84961289174     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121524     Document Type: Article

References (42)

1. Tao H, Junjie W, Yu-Dong C, Hanry Y. Hepatitis C Virus Network Based Classification of Hepatocellular Cirrhosis and Carcinoma. PLoS One 2011; 7(4): e34460.
2. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993; 74(11): 2391-2399. PMID: 8245854
3. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatol. 2005; 42(4): 962-973. PMID: 16149085
4. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol. 2011; 54 (6): 1250-1262. doi: 10.1016/j.jhep.2010.11.016 PMID: 21316497
5. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000; 182(3): 698-700. PMID: 10950762
6. el-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005; 11(33): 5193-5198. PMID: 16127751
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-982. PMID: 12324553
8. Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol. 2010; 3: 37. doi: 10.1186/1756-8722-3-37 PMID: 20925959
9. Guarnieri DJ, DiLeone RJ. MicroRNAs: a new class of gene regulators. Ann Med. 2008; 40: 197-208. doi: 10.1080/07853890701771823 PMID: 18382885
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233. doi: 10.1016/j.cell.2009.01.002 PMID: 19167326
11. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008; 205: 585-594. doi: 10.1084/jem.20072108 PMID: 18299402
12. Williams AE. Functional aspects of animal micro-RNAs. Cell Mol Life Sci. 2008; 65: 545-562. PMID: 17965831
13. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449(7164): 919-922. PMID: 17943132
14. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201. doi: 10.1126/science.1178178 PMID: 19965718
15. Walter HT, Duverlie G, Bengrine A. MicroRNAs and hepatitis C virus: Toward the end of miR-122 supremacy. Virol J. 2012; 9: 109. doi: 10.1186/1743-422X-9-109 PMID: 22691570
16. Zhang G, Wang Q, Xu R. Therapeutics based on microRNA: A New Approach for Liver Cancer. Current Genomics 2010; 11: 311-325. doi: 10.2174/138920210791616671 PMID: 21286309
17. Johannes H, Nicolas Z, Mathias H. The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Eur J Med Sci. 2011; 141: w13287.
18. Ohno O, Mizokami M,Wu R, Saleh MG, Ohba K, Orito E, et al. "New hepatitis c virus (hcv) genotyping system that allows for identification of hcv genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35(1): 201-207. PMID: 8968908
19. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345: 41-52. PMID: 11439948
20. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, et al. Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007; 12(5): 797-803. PMID: 17713163
21. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatol. 2007; 46: 37-47. PMID: 17112624
22. Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011; 5(4): 406-417. doi: 10.5009/gnl.2011.5.4.406 PMID: 22195237
23. Hézode C. Direct-acting antiviral (DAA) actions in treatment-naïve patients. Clin Res Hepatol Gastroenterol. 2011; 35 Suppl 2: S52-58. doi: 10.1016/S2210-7401(11)70008-0 PMID: 22248695
24. Ramachandran S, Basha HI, Sarma NJ, Lin Y, Crippin JS, Chapman WC, et al. Hepatitis C Virus Induced miR200c Down Modulates FAP-1, a Negative Regulator of Src Signaling and Promotes Hepatic Fibrosis. PLoS One 2013; 8(8): e70744. doi: 10.1371/journal.pone.0070744 PMID: 23950995
25. Marquez RT, Bandyopadhyay S, Wendlandt EB, Kathy K, Hoffer BA, Icardi MS, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest. 2010; 90(12): 1727-1736. doi: 10.1038/labinvest.2010.126 PMID: 20625373
26. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011; 50: 136-142. doi: 10.1002/mc.20712 PMID: 21229610
27. Zhang Y, Jia Y, Zheng R, Guo Y,Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010; 56: 1830-1838. doi: 10.1373/clinchem.2010.147850 PMID: 20930130
28. Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008; 4: 77-85. doi: 10.1016/j.chom.2008.05.013 PMID: 18621012
29. Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. Critical evaluation of micro-RNA biomarkers in non-neoplastic disease. PLoS One 2014; 9(2): e89565. doi: 10.1371/journal.pone. 0089565 PMID: 24586876
30. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309(5740): 1577-1581. PMID: 16141076
31. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver specific microRNA miR-122 enhances the replication of hepatitis C virus in non-hepatic cells. J Virol. 2008; 82(16): 8215-8223. doi: 10.1128/JVI.02575-07 PMID: 18550664
32. Villanueva RA, Jangra RK, Yi M, Pyles R, Bourne N, Lemon SM. miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Res. 2010; 88: 119-123. doi: 10.1016/j.antiviral.2010.07.004 PMID: 20637242
33. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008; 27: 3300-3310. doi: 10.1038/emboj.2008.244 PMID: 19020517
34. Roberts APE, Lewis AP, Jopling CL. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 2011; 39: 7716-7729. doi: 10.1093/nar/gkr426 PMID: 21653556
35. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 50 exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci USA. 2012; 110: 1881-1886. doi: 10.1073/pnas.1213515110 PMID: 23248316
36. Pineaua P, Voliniab S, McJunkinc K, Marchioa A, Battistone C, Terris B et al. miR-221 overexpression contributes to liver tumorgenesis. Proc Natl Acad Sci USA. 2010; 107: 264-269. doi: 10.1073/pnas.0907904107 PMID: 20018759
37. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011; 71: 7608-7616. doi: 10.1158/0008-5472.CAN-11-1144 PMID: 22009537
38. Sharma AD, Narain N, Handel EM, Iken M, Singhal N, Cathomen T, et al. MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatol. 2011; 53: 1651-1661.
39. Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, et al. MicroRNA-221 over expression accelerates hepatocyte proliferation during liver regeneration. Hepatol. 2013; 57(1): 299-310.
40. Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA. 2013; 110(19): 7844-7849. doi: 10.1073/pnas.1306138110 PMID: 23613588
41. Shubham S, Anupam M, Ratna RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013; 5(9): 479-486 doi: 10.4254/wjh.v5.i9.479 PMID: 24073299
42. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009; 15(1): 31-33. doi: 10.1038/nm.1902 PMID: 19122656